# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sigmund Freud (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET005-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anton Reinholt, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Five-month review: abstinence, screening results, pain and weight. **S**

## History of present illness

Mr. Freud returns about five months after intake and four weeks after his wellness visit. He has not smoked for fourteen weeks. He takes varenicline 1 mg twice daily and two or three lozenges a day, and the patch was stopped at the wellness visit as planned. He has no muscle aches on atorvastatin 20 mg. The Candida stomatitis has not returned since he began cleaning the obturator nightly and leaving it out at night. His low-dose CT of the chest two weeks ago showed a 4 mm nodule (Lung-RADS 2), mild emphysema and coronary artery calcification; the aortic ultrasound was normal. He has no cough or breathlessness. His pain is 2 of 10, and he has stopped the nutrition supplements because he eats well. **S**

| Element | Detail |
|---|---|
| Tobacco | No smoking for fourteen weeks; varenicline continues; two or three lozenges a day |
| Low-dose CT | Lung-RADS 2; mild emphysema; coronary calcification |
| Aortic ultrasound | 2.7 cm, normal |
| Atorvastatin | 20 mg daily for four weeks; no muscle aches |
| Pain | 2 of 10 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up; energy good |
| Ears, nose, mouth, and throat | Negative | No sore, lump, bleeding or nasal leakage |
| Respiratory | Negative | No cough, breathlessness or blood in sputum |
| Musculoskeletal | Negative | No muscle aches |
| Psychiatric | Negative | Mood steady; occasional brief cravings |

5 systems reviewed. **S**

## Current medications

- Varenicline 1 mg oral tablet, one tablet twice daily after food; planned for at least 24 weeks **S**
- Nicotine 4 mg oral lozenge, one lozenge as needed for cravings, up to 10 a day, dissolved on the side away from the obturator; gum avoided because it sticks to the prosthesis **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain at the maxillectomy site **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 130/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 60.6 kg; BMI 20.5 kg/m². All vital signs are synthetic.

Hemoglobin: 13.8 g/dL; MCV: 92 fL; Albumin: 3.9 g/dL; Creatinine: 0.98 mg/dL; eGFR (CKD-EPI 2021): 81 mL/min/1.73 m²; ALT: 25 U/L; Pain score (0 to 10): 2. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.2 g/dL (low) at baseline, 13.8 g/dL at this visit **S**
- MCV: 93 fL at baseline, 92 fL at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.9 g/dL at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 0.98 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 83 mL/min/1.73 m² at baseline, 81 mL/min/1.73 m² at this visit **S**
- ALT: 22 U/L at baseline, 25 U/L at this visit **S**
- Pain score (0 to 10): 6 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 130/78, pulse 68; weight 60.6 kg |
| Mouth | Mucosa healthy; no plaques, ulcer, mass or white or red patch; obturator clean and well fitting |
| Neck | No lymph nodes felt |
| Respiratory | Clear to auscultation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Tobacco use disorder, severe, in early remission** (F17.290). Fourteen weeks without smoking. **S**
   - Complete 24 weeks of varenicline next month, then stop; continue it longer if cravings return.
   - Taper lozenges over the next month.
   - Spirometry at the next visit for the emphysema seen on CT.
2. **History of palatal squamous cell carcinoma** (Z85.818). No sign of recurrence. Screening CT Lung-RADS 2: a small nodule that needs only the yearly screening scan. **S**
   - Low-dose CT in 12 months while he remains eligible and fit for treatment.
   - Surgeon's yearly examination next summer.
3. **Raised LDL cholesterol with a high cardiovascular risk** (E78.5). Coronary artery calcification on CT supports the statin. ALT normal and no muscle symptoms. **S**
   - Continue atorvastatin 20 mg daily; lipid panel at the yearly review.
4. **Weight loss** (R63.4). Weight 60.6 kg, albumin 3.9 g/dL and hemoglobin 13.8 g/dL: recovered. **S**
   - Supplements stopped; weight at each visit.
5. **Chronic pain at the maxillectomy site** (G89.29). Pain 2 of 10 with the new obturator. **S**
   - Continue acetaminophen 1,000 mg three times daily for now; he may try taking it only when needed if the pain stays at 2 of 10.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Tobacco use (cigars a day), readiness and quit date | Every visit | Completed today | No smoking for fourteen weeks; exhaled carbon monoxide 3 ppm (narrative) |
| Medication safety | Varenicline adherence and side effects (nausea, sleep, dreams, mood) | Every visit; at least 12 weeks, extended to 24 weeks or more | Completed today | 1 mg twice daily; no side effects; to complete 24 weeks next month |
| Medication safety | Combination nicotine replacement (patch and lozenge) | From the quit date for at least 8 to 12 weeks | Completed today | Patch finished after ten weeks; lozenges two or three a day, to taper |
| Self-management | Behavioral support (quitline and clinic sessions) | Weekly calls around the quit date, then every two to four weeks | Completed today | Quitline every two weeks; final call next month |
| Self-management | Relapse prevention | Every visit | Completed today | No slips since the second week |
| Laboratory | Kidney function for varenicline dosing | Baseline; again if illness or new medicines | Completed today | Creatinine 0.98 mg/dL, eGFR 81 |
| Examination | Head and neck surveillance examination (mouth, defect and neck) | Yearly by his head and neck surgeon more than five years after treatment; mouth checked at each visit | Completed today | Mouth and neck normal today; surgeon's next yearly examination next summer |
| Imaging | Head and neck imaging | Only for symptoms or signs more than five years after treatment | Not indicated | No symptoms or signs |
| Imaging | Lung cancer screening eligibility | Yearly low-dose CT when chosen by shared decision | Completed today | Low-dose CT two weeks ago: Lung-RADS 2; next in 12 months |
| Examination | Obturator fit, seal and hygiene | Every visit | Completed today | Obturator clean and well fitting; nightly cleaning and overnight removal continue |
| Examination | Speech and swallowing (hypernasality, nasal leakage) | Every visit; speech-language therapy as needed | Completed today | Therapy course finished; normal resonance |
| Self-management | Dental care (high-fluoride toothpaste, cleaning every three months) | Daily toothpaste; cleaning every three months | Completed today | Dental cleaning last month |
| Examination | Weight and nutrition | Every visit | Completed today | 60.6 kg; supplements stopped |
| Laboratory | Albumin | Baseline and at three months while weight is recovering | Completed today | Albumin 3.9 g/dL; hemoglobin 13.8 g/dL, MCV 92 fL |
| Laboratory | ALT and muscle symptoms on atorvastatin | Baseline, then if symptoms | Completed today | ALT 25 U/L; no muscle symptoms |
| Survey | Pain score and function | Every visit | Completed today | 2 of 10 |
| Medication safety | Acetaminophen daily dose (no more than 3,000 mg) | Every visit | Completed today | 3,000 mg a day; may move to as needed |
| Medication safety | Opioids | Avoid long-term opioids | Not indicated | Not needed |

## Goal progress

- Stop smoking cigars completely, at a pace he chooses, using varenicline and nicotine replacement. Outcome by 2026-10-26: Twenty cigars a day to six by six weeks; no smoking since the quit date apart from one cigar in the second week; about fourteen weeks without smoking at five months. **S**
- An obturator that seals and does not rub, so that speech is clear and liquids do not leak into his nose. Outcome by 2026-08-24: Reline at two weeks; new definitive obturator fitted at twelve weeks; speech clear and no nasal leakage. **S**
- Pain at 3 of 10 or less without opioids. Outcome by 2026-10-26: Pain 6 to 2 of 10 on scheduled acetaminophen with a well-fitting obturator. **S**
- Regain weight to at least 60 kg with a normal albumin. Outcome by 2026-10-26: Weight 58.4 to 60.6 kg; albumin 3.4 to 3.9 g/dL. **S**

## Guideline basis

- Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(2):e5-e31)
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 2.2026 (follow-up and survivorship) (2026), National Comprehensive Cancer Network
- American Cancer Society Head and Neck Cancer Survivorship Care Guideline (2016), American Cancer Society (CA Cancer J Clin 2016;66(3):203-239)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force

## Follow-up

- Stop varenicline after 24 weeks next month. Review in three months with spirometry. Low-dose CT and the surgeon's examination yearly. Next wellness visit in one year. **S**

